Evidence map›Paper›PMID 42635429›Full record

ArticleJournal of virology2026

HIV DNA and transcription before and after ART in natural controllers compared to noncontrollers.

Sun Jin Kim, Julie Janssens, Cordelia Isbell, Adam Wedrychowski, Alton Barbehenn, Rebecca Hoh, Michael J Peluso, Sulggi A Lee, Satish K Pillai, Timothy J Henrich and 3 more

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sun Jin KimDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Julie JanssensDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Cordelia IsbellDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Adam WedrychowskiDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Alton BarbehennDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Rebecca HohDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Michael J PelusoDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Sulggi A LeeDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Satish K PillaiDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.ORCID 0000-0001-8770-7014
Timothy J HenrichDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.
Nadia R RoanDepartment of Urology, University of California, San Francisco (UCSF), San Francisco, California, USA.
Steven G DeeksDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.ORCID 0000-0001-6371-747X
Steven A YuklDepartment of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.ORCID 0000-0002-4578-9872

Funding

Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
The heterogeneous HIV expressing reservoir: dynamics, persistence mechanisms, tissue distribution, and contribution to reboundP01AI169606 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Steven A Yukl · 2022 to 2026
$9.3M
Novel single genome approaches to determine the mechanisms of HIV latent infection in blood, gut, and lymph nodesR01DK120387 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI LICHTERFELD, MATHIAS, YUKL, STEVEN A · 2019 to 2023
$4.1M
Understanding and targeting the HIV-expressing reservoir to reduce immune activationR01AI183666 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER W HUNT, Steven A Yukl · 2024 to 2026
$2.4M
A pharmacogenomics study of HIV latency: the role of PD-1 signalingK23GM112526 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, SULGGI ANGELA · 2014 to 2018
$908k
amfAR, The Foundation for AIDS Research 108072-50-RGRLBill and Melinda Gates Foundation INV-002703Bill & Melinda Gates Foundation INV-002703Gilead Sciences IN-US-236-1354National Institute of Allergy and Infectious Diseases P01AI169606National Institute of Allergy and Infectious Diseases R01AI183666NIAID NIH HHS P01 AI169606NIAID NIH HHS R01 AI183666NIAID NIH HHS UM1 AI164560NIDDK NIH HHS R01 DK120387NIDDK NIH HHS R01DK120387NIGMS NIH HHS K23 GM112526NIH HHS K23GM112526NIH HHS UM1AI164560ViiV Healthcare A126326
6 · The paper itself

Abstract

HIV-1 natural controllers can limit plasma HIV RNA levels in the absence of antiretroviral therapy (ART). Although controllers have less HIV DNA, it remains unclear how HIV transcription differs from noncontrollers, and whether ART further reduces HIV DNA or RNA in controllers. To address these questions, we quantified different HIV transcripts and HIV DNA regions/proviruses in longitudinal blood samples collected before ART and up to 3-5 years on suppressive ART from 10 controllers (5 "elite" and 5 viremic) and compared them to ART-suppressed noncontrollers. Compared to noncontrollers, controllers exhibited lower levels of most HIV DNA regions (but not intact proviruses) and lower total levels of initiated and completed HIV RNA, but paradoxically higher levels per provirus of initiated and 5' elongated HIV transcripts. Controllers also showed a lower ratio of completed/elongated HIV RNA. After ART, controllers showed lower levels of multiply spliced HIV RNA and a lower ratio of multiply spliced/completed HIV RNA. These results suggest that natural controllers limit HIV infection frequency and selectively restrict HIV transcript completion and splicing. ART treatment of controllers led to further increases in CD4 counts and decreases in HIV DNA and some HIV transcripts, supporting the potential for clinical benefits in this population.IMPORTANCENatural HIV controllers can suppress HIV-1 replication without antiretroviral therapy (ART) and serve as a model for an HIV functional cure, but the mechanisms are unclear. We found that natural control was associated with mechanisms that reduce levels of total HIV DNA and the HIV promoter regions to below the levels seen in ART-treated noncontrollers (NC), resulting in lower total levels of most HIV transcripts. When corrected for HIV DNA levels, natural controllers exhibited higher levels per provirus of short, prematurely terminated HIV transcripts but lower proportions of completed and spliced HIV transcripts. These findings suggest that the mechanisms of natural control do not only limit HIV infection frequency, but specifically limit production or increase clearance of infected cells making completed and spliced HIV transcripts. ART treatment of controllers led to further increases in CD4

Indexed as

DNA, ViralElite ControllersHIV-1HIV InfectionsViral TranscriptionHumansProvirusesRNA, ViralTranscription, GeneticViral LoadDNA, ViralRNA, ViralcontrollerDNAHIVHIV-1provirusRNAtranscription

Identifiers

PMID42635429
PMCPMC13595968

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.